Traumatic brain injury (TBI) results in cognitive impairment, which can be long-lasting after moderate to severe TBI. Currently, there are no FDA-approved therapeutics to treat the devastating consequences of TBI and improve recovery. This study utilizes a prodrug of 2,4-dinitrophenol, MP201, a mitochondrial uncoupler with extended elimination time, that was administered after TBI to target mitochondrial dysfunction, a hallmark of TBI. Using a model of cortical impact in male C57/BL6 mice, MP201 (80 mg/kg) was provided via oral gavage 2-hr post-injury and daily afterwards. At 25-hr post-injury, mice were euthanized and the acute rescue of mitochondrial bioenergetics was assessed demonstrating a significant improvement in both the ipsilateral cortex and ipsilateral hippocampus after treatment with MP201. Additionally, oxidative markers, 4-hydroxyneneal and protein carbonyls, were reduced compared to vehicle animals after MP201 administration. At 2-weeks post-injury, mice treated with MP201 post-injury (80 mg/kg; q.d.) displayed significantly increased cortical sparing (p 5 .0059; 38% lesion spared) and improved cognitive outcome (p 5 .0133) compared to vehicle-treated mice. Additionally, vehicle-treated mice had significantly lower (p 5 .0019) CA3 neuron count compared to sham while MP201-treated mice were not significantly different from sham levels. These results suggest that acute mitochondrial dysfunction can be targeted to impart neuroprotection from reactive oxygen species, but chronic administration may have an added benefit in recovery. This study highlights the potential for safe, effective therapy by MP201 to alleviate negative outcomes of TBI.
relate to increased reactive oxygen species (ROS) production, oxidative damage, and eventual cell death (Sullivan, Thompson, & Scheff, 2000; Sullivan et al., 1998; Hubbard, Davis, & Sullivan, 2018) . In vitro studies show that decreasing membrane potential (w) can cause a significant reduction in excitotoxic cell death (Nicholls & Budd, 1998; Stout, Raphael, Kanterewicz, Klann, & Reynolds, 1998) . In addition, endogenous mitochondrial uncouplers (UCPs) utilize free fatty acids to translocate protons across the inner membrane thereby decreasing mitochondrial membrane potential and reducing cell death. While UCP1's relationship to ROS levels is undetermined, UCPs 2 and 3 are activated by ROS therefore providing a negative feedback loop for mitochondrial-derived ROS. It has also been demonstrated that modification of glutathione controls UCP2 and 3 activity (Mailloux & Harper, 2011) . Our group has shown that upregulating UCP2 can decrease ROS production and cell death while dietary reduction of UCP levels elevate ROS (Sullivan, Dube, Dorenbos, Steward, & Baram, 2003; Sullivan, Springer, Hall, & Scheff, 2004) . After TBI, overexpression of UCP2 also reduces ROS production and increases cortical sparing (Mattiasson et al., 2003) .
Many preclinical studies aimed at targeting mitochondrial dysfunction after TBI have proven successful, including pharmacological modulation of mitochondrial physiology by uncoupling agents (i.e., 2,4-dinitrophenol [DNP] ). Our group has published multiple reports outlining the neuroprotective therapy of mitochondrial uncouplers carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) and DNP (Korde, Sullivan, & Maragos, 2005b; Maragos, Rockich, Dean, & Young, 2003; Pandya, Pauly, & Sullivan, 2009; Pandya et al., 2007) , though this success has not yet been validated in the clinic. These studies find that administration of optimal dosage of these uncoupling agents will impart greater tissue and neuronal sparing, as well as improved behavioral outcomes compared to placebo groups (Pandya et al., 2007) . There is also reduction in oxidative damage, Ca 21 overloading, and increased mitochondrial respiration associated with brain injury. In addition to the immediate benefits of mitochondrial uncouplers to lower ROS production and resolve calcium over-load, which is primarily based upon biophysics, the uses of DNP under chronic treatment has shown a benefit to induce endogenous levels of a critical growth factor, brain-derived neurotrophic factor (BDNF) and improve cognitive function in a model of Alzheimer's disease (AD; Geisler, Marosi, Halpern, & Mattson, 2017) .
In addition, in a model of Huntington Disease after 17 weeks of treatment, DNP slowed brain volume loss, which was associated with sparing of both medium spiny neurons (DARP32) and general neurons (PSD95), and behavioral outcomes (movement) (Wu et al., 2017) .
Mild (low doses) uncoupling with DNP has proven to potentially become a valid therapy today for serious neurodegenerative diseases, in comparison to its uses for obesity in the 1930s when provided to over 100,000 humans at high doses and calling for its eventual ban by the FDA in 1937 since it was never actually approved as a drug (Harris & Corcoran, 1995) . In fact, the doses of DNP for neuroprotection are many fold lower than the doses used for obesity commonly at 300 mg daily. For instance, in the APP/PS1 double mutant mouse model of AD, 4 months of chronic once-per-day oral treatment with DNP showed that an extremely low dose of 0.5 mg/kg (eq. 2 mg in humans) was sufficient to have a striking effect on both learning and preservation of short-term memory, hallmarks of this devastating disease . Whereas in model of epilepsy , a dose of DNP at 5 mg/kg (103 higher than AD) was significant to reduce seizures activity by 103 (eq. to 20 mg daily in humans), but a mid-dose of 1 mg/kg appeared optimal in preserving brain volume in a model of Huntington's disease, equivalent to 5 mg daily for patients (Wu et al., 2017) . These low doses should translate to a well-tolerated treatment in the patient population for insidious neurodegenerative diseases and paradoxically likely weight neutral or even weight preserving in wasting syndromes as a stand-alone therapy Wu et al., 2017) . DNP also has the advantage over other uncouplers in this unique platform since it is relatively a weak uncoupling agent with a considerably larger safety index in comparison to others in this platform such as FCCP or carbonyl cyanide m-chlorophenyl hydrazone (CCCP), which are strong uncouplers with a narrow safety window (Lou et al., 2007) . Although strong uncouplers like FCCP/CCCP are not useful as a therapeutic agent for humans, they can be useful in preclinical models to demonstrate this platform's overall effects on abolishing ROS and tissue sparing (Pandya et al., 2007 . Nevertheless, to improve upon the pharmacokinetics of DNP, a novel prodrug of DNP was synthesized with a 203 lower Cmax and 33 longer elimination time called MP201.
MP201 was previously tested in a model of optic neuritis and shown to have a striking effect on preventing vision loss by preserving retinal ganglion cells and protection of the axon form demyelination (Khan, Dine, Geisler, & Shindler, 2017) . Our group now seeks to verify the neuroprotective effects of MP201 after TBI, in order to highlight its clinical potential. In addition, the longer residence time may further improve upon the benefits seen previously with DNP alone after TBI (Pandya et al., 2007) . We hypothesize that MP201 administration after TBI will restore mitochondrial function, mitigate oxidative stress, and improve cognition. were used in both detailed experiments and randomly assigned to groups using a random number generator. Mice were housed (five per cage) in a 12 hr light/dark cycle with food and water available ad libitum. They had a 1-week acclimation period to the vivarium before experiments commenced. For this initial study, male mice were utilized first due to higher incidence, higher rate of comorbidities, and the potential neuroprotective effect of female sex hormones, though we do acknowledge this is a limitation (Berry et al., 2009; Xiong, Mahmood, & Chopp, 2013) . For all assessments, three treatment groups were utilized: sham-injured 1 vehicle, controlled cortical impact (CCI)-injured 1 vehicle, and CCI-injured 1 MP201. For mitochondrial assessments, animals (n 5 3-4/group) were given either vehicle or MP201 2-hr post-injury and again 24 hr-post-injury, 1 hr before killing. For behavior and histology assessments, animals (n 5 8-12/group) were given either vehicle or MP201 via oral gavage 2 hr post-injury and again every morning until 14 days post-injury. Once per day administration of MP201 was used to give constant on-board mild mitochondrial to induce low levels of DNP over time (Khan et al., 2017 (Khan et al., 2017) . This dose has been tested to provide therapy with no negative consequences on weight loss. Mice were given 10 ml/kg or approximately 250 ml of solution (depending on weight) at each dose of MP201 or vehicle depending upon group designation.
| Mouse model of focal (lateral controlled cortical impact) TBI
Injury procedures were similar as previous published studies (Singh, Sullivan, Deng, Mbye, & Hall, 2006) . Mice were initially anesthetized in a plexiglass chamber using 4.0% isoflurane and placed in a stereotaxic frame. During the injury procedure, anesthesia was maintained with 2.5% isoflurane delivered via a nose cone. The head was positioned in the horizontal plane with the nose bar set at zero. After an incision exposing the skull, a 4-mm craniotomy was made lateral to the sagittal suture and centered between the bregma and lambda. The skull cap at the craniotomy was carefully removed without damaging the underlying dura, and the exposed cortex was injured using a pneumatically controlled impactor device as described previously . The impactor tip diameter was 3 mm and the impact velocity was set at 3.5 m/s with a cortical depth of 1.0 mm. After injury, the craniotomy was closed by placement of a 6 mm sterile plastic disk glued over the site. The animals were then placed in a recovery cage over a heating pad at 37 8C until consciousness (i.e., return of righting reflex and mobility) was regained to prevent hypothermia. A sham group was included which underwent anesthesia and a craniotomy, but no cortical impact or injury.
| Isolation of mitochondria from brain tissue
Mitochondrial isolation protocol was adapted from the previously described protocols with modifications (Brown et al., 2004; Nukala, Singh, Davis, & Sullivan, 2006; Pandya, Nukala, & Sullivan, 2013; Vekaria, Talley Watts, Lin, & Sullivan, 2017) . All the steps were carried out at 4 8C or on ice. After mice were euthanized with CO 2 , the ipsilateral cortex and ipsilateral hippocampus were dissected out and homogenized using Teflon-glass dounce homogenizer containing isolation buffer ferred to 2 ml micro centrifuge tube and spun at 1,300 3 g for 3 min.
The supernatant was further transferred in a fresh 2 ml micro centrifuge tube and spun at 13,000 3 g for 10 min. The supernatant was discarded and the crude mitochondrial pellet was resuspended in 400 ml of isolation buffer. This suspension was added to a pressurized nitrogen cell disruptor at 1,200 psi for 10 min at 4 8C to release the synaptic mitochondria from the synaptosomes. The suspension of total mitochondria was then transferred to 1.5 ml micro centrifuge tubes and pelleted at 10,000 3 g for 10 min. The supernatants were discarded and the total mitochondrial pellets were resuspended in EGTA-free isolation buffer to get 10 mg/ml approximate concentration of mitochondria. The absolute protein concentration was determined using bicinchoninic acid Chain using previous methods with slight modifications (Pandya et al., 2016; Patel et al., 2014; Sauerbeck et al., 2011; Vekaria et al., 2017) . The stocks used for the assays are 500 mM pyruvate, 250 mM malate, and 30 mM adenosine diphosphate (ADP), and 1 M succinate (pH for all were adjusted to 7.2) plus assay solutions of 1 mg/ml (1.26 mM) oligomycin A, assay plates were used separately for loading mitochondria. Initially total mitochondria were diluted to 10 mg/50 ml in RB and 50 ml was loaded in each well resulting in 10 mg mitochondria/well. The assay plates were centrifuged at 3,000 rpm for 4 min at 4 8C to adhere the mitochondria at the bottom of the wells. After centrifugation, 475 ml RB (preincubated to 37 8C) was added without disturbing the mitochondrial layer to obtain a final volume of 525 ml per well. After the instrument calibration with the sensor cartridge was complete, the utility plate was replaced by the plate loaded with mitochondria for bioenergetics analysis. The assays were carried out under previously optimized protocol (Sauerbeck et al., 2011 
| Oxidative stress assays
Mitochondrial homogenate aliquots (unused during respiration assays)
were kept at 220 8C until utilization for oxidative stress blots. Three separate markers, 4-hydroxeneal (HNE), 3-nitrotyrosine (3-NT), and protein carbonyls (PC), were assessed in these samples. Protein concentrations were determined using a BCA (Pierce, Rockford, IL) protein assay. For PC, 5 ml of sample, 5 ml of Sodium dodecyl sulfate (SDS) (12% solution in H 2 O), and 10 ml of 2,4-dinitrophenylhydrazine (1:10 dilution in phosphate-buffered saline [PBS] ) was added to a 0.6 ml Eppendorf tube. Neutralization buffer (7.5 ml) was then added to each sample assayed for PC.
For HNE, and 3-NT, 5 ml of sample, 5 ml of 12% SDS and 10 ml of Laemmili buffer (0.125 M Trizma base, 4% SDS, and 20% glycerol) was added to a 0.6 ml Eppendorf tube without neutralization buffer. All samples were incubated at room temperature for 20 min. Protein concentration of the sample was titrated to 1 ng/ml in a 2 ml Eppendorf tube.
The BioRad Bio-Dot SF Microfiltration System was assembled by placing three Filter Papers in the lower Bio-Dot tray followed by the nitrocellulose membrane. The Bio-Dot system was then attached to a laboratory vacuum system and washed with 250 ml of PBS. After the PBS wash, each sample was vortexed and then loaded into the upper tray. Each sample was loaded into two "slots" in proximity. The samples were then processed onto the membrane by vacuum. The membrane was then removed, marked, and left to dry overnight. Blocking solution antibodies were characterized using appropriate positive and negative controls. The appropriate antibody solutions (Table 1) were added to the trays and allowed to incubate for 120 min on the rocker. After 120 min, the antibody solutions were removed and the membranes were washed thrice 5 min each. The secondary antibody solution was made using 2.5 ml of Anti-Rabbit IgG alkaline phosphatase produced in goat (Sigma-Aldrich) added to 20 ml Wash-Blot Solution. The membranes were incubated with the secondary antibody for 60 min. The membranes were then washed.
Developing solution was then prepared using 30 ml of alkaline phosphatase (ALP) buffer, 99 ml of 5-bromo-4-chloro-3-indolyl phosphate, and 198 ml of NBT (nitroblue tetrazolium) and added to trays. Membranes were allowed to develop and then washed with D.I. water and allowed to dry overnight. The next day the membranes were scanned with a photo scanner (Epson Perfection V600, Long Beach, CA), and slot-blot line densities were quantified by the ImageQuant TL software package (GE Healthcare Bio-Sciences, Piscataway, NJ; RRID:SCR_014246). 
| Novel object recognition test

| Stereology
After a survival of 15 days, the animals were anesthetized by an over- 
| Lesion volume assessment
For lesion volume analysis, sections (35 mm) were stained with cresyl violet and subjected to image analysis (ImageJ, NIH, RRID:SCR_ 003070). Quantitative assessment of cortical damage employed an unbiased stereological protocol, the Cavalieri method, as described previously Sullivan et al., 2000 Sullivan et al., , 2002 . Briefly, a systematic random subset of sections (minimum of 12), separated by a known distance (d), was selected for analysis. On each section, the total cortical area, defined as the dorsal aspect of lamina I to the dorsal aspect of the corpus callosum, was determined for the entire hemisphere. Each area was multiplied by d to calculate a subvolume. All of the subvolumes were then summed to yield the total volume. The volume of the contralateral hemisphere was also determined in an identical fashion, and tissue sparing in the injured hemisphere was expressed as a percentage of the total cortical volume for that (contralateral) hemisphere.
| Statistical analysis
Statistical analysis was performed using Graph Pad Prism (GraphPad Software, CA; RRID:SCR_002798). For all analyses, the significance of differences among groups was set at p < .05. For each measure, data were measured using interval/ratio scales. The Brown-Forsythe and Bartlett's tests were performed to ensure homogeneity of variance. Furthermore, the Shapiro-Wilk test was completed to ensure normality.
As these criteria were met for all experimental data, parametric statistics were employed for all analyses. Statistical outliers were identified by internally studentized residuals and excluded if this value was 6 2.
No outliers were removed for the mitochondrial, oxidative damage marker, or lesion volume data sets. For the behavior data, two data points were removed for the Sham group and one data point from the MP201-treated group, based on studentized residuals, to give n 5 10 and n 5 11 for these groups, respectively. For mitochondrial assessments and stereological neuron counts, data sets were evaluated using an analysis of variance (ANOVA), and when appropriate, post hoc comparisons employing the Fisher's LSD test. For cortical sparing, an unpaired t-test was used to determine significance between the groups. For behavioral scores, data sets were evaluated using a repeated measures analysis of variance followed by post hoc comparison employing the Fisher's LSD test. Power analysis was calculated for mitochondria experiments using the following assumptions: a 5 0.05, 1 2 b 5 0.8, and standard deviation 10% of mean for three groups (Charan & Kantharia, 2013) . Similarly, power analysis was calculated for behavioral experiments using the following assumptions: a 5 0.05, 1 2 b 5 0.8, and standard deviation 25% of mean for three groups.
| R E SU LTS
| MP201 restores mitochondrial bioenergetics
It is well-known that TBI causes impaired mitochondrial respiration (Sullivan et al., 1998 (Sullivan et al., , 2000 Xiong, Gu, Peterson, Muizelaar, & Lee, 1997 (Figure 1 ). This same profile is also observed for maximum respiration of complex II (in presence of FCCP and succinate), or State V (Suc) respiration, for ipsilateral cortex (F 5 29.03, n 5 3, p 5 .0003). There is also no significant difference in State IV-mediated respiration in the cortex between all groups, demonstrating that there is no excessive proton leak in mitochondria after MP201 treatment. This is most likely due to the uncoupler being "washed" out during the mitochondrial isolation procedure as previously documented by ours and other groups (Jin et al., 2004; Pandya et al., 2007 Pandya et al., , 2009 Patel, Sullivan, Pandya, & Rabchevsky, 2009 ). 
| MP201 reduces presence of mitochondrialderived oxidative stress in tissue
Oxidative stress is a common mechanism observed after TBI and dysfunctional mitochondria are major sources of ROS (Hiebert, Shen, 3.3 | MP201 administration leads to cognitive improvement, elevated levels of CA3 neurons, and increased tissue sparing after TBI TBI is well-known to produce cognitive impairment and this can be consistently replicated in animal models using the NOR paradigm (Bolton Hall et al., 2016; Davis et al., 2010; Srodulski et al., 2014) . At 2-weeks post-injury, MP201-treated animals display significantly higher recognition index score (F 5 3.826, n 5 12/group, p 5 .0133) compared 
| D ISC USSION
The results garnered from this study reaffirm the crucial role of mitochondria in secondary mechanisms after TBI. The studies highlight the importance of proper mitochondrial function to restore cognition and memory after TBI. Injury-induced changes in mitochondrial respiration from the cortex and hippocampus are restored by oral, once daily administration of MP201. This improvement in mitochondrial bioenergetics appears to be the mechanism driving a significant reduction in lesion volume and CA3 neuronal preservation at 2-weeks post-injury.
Importantly, the mild uncoupling induced by MP201 does not translate into fully uncoupled isolated mitochondria as evidenced in our assays, but is consistent in DNP chronic administration improving cognition and neuroprotection Liu et al., 2015; Wu et al., 2017) .
We find that MP201 administration significantly increases state III respiration in the ipsilateral cortex 25 hr after TBI as well as increases complex II-mediated state V respiration compared to vehicle-treated animals. Mild uncoupling imparted by MP201 lowers DWm and reduces the Ca 21 cycling leading to better ADP driven mitochondrial function.
Similarly, state III respiration and state V respiration through complex I are increased after MP201 treatment compared to vehicle-injured mice at 25 hr after TBI. We speculate that this leads to decreased oxidative stress and cell death in the hippocampus, thereby restoring cognitive function.
It is known that mitochondrial dysfunction and oxidative damage are intertwining processes that occur in response to TBI. As mitochondria normally produce basal levels of ROS, they are a constant source of ROS in cells. We observe an increase in mitochondrial-derived HNE and PC after vehicle treatment and injury compared to sham. There is no significant increase in MP201-injured animals compared to sham.
We hypothesize that a reduction in DWm due to MP201 is the mechanism by which ROS decrease after TBI (Liu, Fiskum, & Schubert, 2002; Starkov & Fiskum, 2003; Starkov, Polster, & Fiskum, 2002) . Though, the reduction in ROS could be directly due to an initial reduction in mitochondrial Ca 21 overloading that accompanies uncoupling by our prodrug (Mattiasson, 2004; Sullivan et al., 2005) .
Cognitive outcome is a crucial measure when assessing benefits of therapies on long-term behavior and the NOR test is commonly used to assessment memory after TBI (Bolton Hall et al., 2016; Davis et al., 2010; Srodulski et al., 2014) . While a lack of cognitive improvement is observed after MP201 treatment at 1-week post-injury, there is a significant increase in novel object memory score at 2-weeks post-injury in MP201-treated animals. This recovery of normal cognitive function using the NOR test is not normally seen after injury (Han et al., 2011; Watanabe et al., 2013) , evidenced by the vehicle-injured group. These results are supported by hippocampal neuron counts in the CA3. The loss of CA3 neurons is a common feature of experimental models of TBI and this loss is associated with cognitive impairment (Grady, Charleston, Maris, Witgen, & Lifshitz, 2003; Li et al., 2013; Witgen et al., 2005 As mentioned previously, our group has demonstrated that FCCP and DNP improve outcome following TBI (Pandya et al., 2007 ).
To improve pharmacology compared to these uncoupling agents, MP201 offers increased residence time due to its prodrug pharmacokinetics of slower elimination time, potentially offering a greater safety margin, but also strong patent protection. In this current study, we have shown that MP201 produces similar results as other mitochondrial uncoupling agents. In brief, this platform of mitochondrial uncoupling agents can increase proton leakage across, thereby lowering DWm and reducing oxidative stress (Cannon & Nedergaard, 2004; Jarmuszkiewicz, Czarna, Sluse-Goffart, & Sluse, 2004; Pandya et al., 2007 Pandya et al., , 2009 Sluse et al., 2006; Sullivan et al., 2004) . In this manner, beneficial outcomes are observed after mild uncoupling therapy in response to traumatic insult to the brain. Additionally, DWm is the driving force for Ca 21 influx from the cytoplasm to the mitochondria, so mild mitochondrial uncoupling also lowers mitochondrial Ca 21 overload, which prevents the opening of the mitochondrial permeability transition pore; the beginning of eminent death for the cell (Gunter, Gunter, Sheu, & Gavin, 1994; Mattiasson et al., 2003) .
Preclinical TBI studies have long used cortical sparing as a neuroprotective measure (Pandya et al., 2007; Sullivan et al., 2000) . In the present study, there is a marked decrease in the lesion volume (38%) with MP201 treatment compared to vehicle.
After TBI, Ca 21 uptake by mitochondrial leads to dysfunction and subsequent cell death, especially around the lesion site. Lowering DWm by MP201 administration reduces this Ca 21 cycling in mitochondria thereby reducing excitotoxic cell death (Nicholls & Budd, 1998) . Additionally, DNP is known to induce BDNF under chronic treatment, which potentially could promote neuronal growth over time . This reduction in neuronal cell death at the injury site is highlighted by increased cortical sparing in the MP201-injured mice.
While this study highlights the importance of targeting mitochondrial dysfunction after TBI, the exciting results lie in the neuroprotective therapy. Since mitochondria are evolutionarily conserved and the mitochondrial uncoupling mechanism of action is initially nongenomic based upon biophysics rather than a protein pathway, which are not always well conserved from rodents to humans, translation is predicted to be excellent (Geisler, 2011; Miwa & Brand, 2003) . Prodrugs are typically used for drugs with poor absorption or poor transport across the blood-brain barrier (Clond et al., 2013; Feng et al., 2012) , however in the case of DNP, it is employed to slow elimination thereby providing a "trickle-like" effect of providing DNP's bioavailability. This longer residence time can provide sustained neuroprotection with lowering ROS, mitigating on-going apoptosis and potentially raising BDNF, which could restore some neural connections as a growth factor (da Costa, Martinez, & Ferreira, 2010; De Felice & Ferreira, 2006; Korde, Pettigrew, Craddock, & Maragos, 2005a) . Since time is critical after a concussion or TBI to block the penumbra from releasing ROS and killing the surrounding cells, MP201 should be considered as a first line therapy to protect the threatened tissue. Literature shows that chronic, controlled-release DNP administration results in no evidence of toxic effects in mice (Cutting, Mehrtens, & Tainter, 1933; Perry, Zhang, Zhang, Boyer, & Shulman, 2015) , thereby lending itself to potential chronic administration. In the current study, we utilize a clinically relevant therapeutic window for initiation of treatment of 2-hr post-injury.
On-going experiments are assessing the extent of this therapeutic window as we have demonstrated a window of at least 24-hr post-injury for other mitochondrial uncouplers . For situations such as in a military setting where the risks of TBI are high and predicted, prophylactic treatment could be considered, thereby providing the benefits of lowering ROS and higher BDNF levels a priori. Although sexual dimorphism is not likely to play a major role in the pharmacology of this platform, incorporating both sexes to determine any possible preferential therapeutic sex effects is merited in follow-up studies.
Overall, this study presents data showing the therapeutic potential of MP201, a mitochondrial uncoupling prodrug of DNP. By restoring mitochondrial bioenergetics acutely, consistent administration leads to improvement in cortical sparing, CA3 neuron counts and behavioral outcome. Early targeting of mitochondrial dysfunction after injury seems pivotal to mitigation of downstream processes (oxidative stress) and improved outcome. Improved mitochondrial function and stabilization of oxidative phosphorylation acutely combines with a restoration of ROS balance over time to create a pleiotropic therapeutic effect by MP201 to improve cognitive function and cortical sparing. Ongoing studies will assess the optimal dose and therapeutic window of opportunity for MP201 following TBI to build upon the current results and tease out these multifaceted effects. Future studies will assess MP201 in a model of mild TBI as is necessary to determine translatable ability.
It is crucial that preclinical studies of TBI incorporate novel and highly translatable therapies, as we believe MP201 is in this study.
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